Patient characteristics and treatment pathways in patients with asthma or asthma-COPD overlap treated with Medium-Strength ICS/LABA and switching to High-StrEngth ICS/LABA or Medium-Strength TRImbow (BETRI)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/1000000205
• EU PAS number:
  EUPAS1000000205
• Study ID:
  1000000205
• Official title and acronym:
  Patient characteristics and treatment pathways in patients with asthma or asthma-COPD overlap treated with Medium-Strength ICS/LABA and switching to High-StrEngth ICS/LABA or Medium-Strength TRImbow (BETRI)
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  Effects of switching to triple therapy versus escalation of dual therapy regimen in patients with asthma or asthma-COPD overlap treated with medium-strength dual therapy
• Study status:
  Ongoing

Research institutions and networks

Institutions

Observational & Pragmatic Research Institute Pte (OPRI)

United Kingdom

Study timelines

Date when funding contract was signed

Planned: 21/02/2024

Actual: 21/02/2024

Study start date

Planned: 06/06/2024

Actual: 06/06/2024

Data analysis start date

Planned: 29/07/2024

Date of final study report

Planned: 31/03/2025

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Chiesi Farmaceutici S.p.A.

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable